JP2008505087A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505087A5
JP2008505087A5 JP2007519344A JP2007519344A JP2008505087A5 JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5 JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5
Authority
JP
Japan
Prior art keywords
glucagon
insulin
amount
milliunits
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/022812 external-priority patent/WO2006004696A2/en
Publication of JP2008505087A publication Critical patent/JP2008505087A/ja
Publication of JP2008505087A5 publication Critical patent/JP2008505087A5/ja
Pending legal-status Critical Current

Links

JP2007519344A 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 Pending JP2008505087A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (2)

Publication Number Publication Date
JP2008505087A JP2008505087A (ja) 2008-02-21
JP2008505087A5 true JP2008505087A5 (enExample) 2008-07-31

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519344A Pending JP2008505087A (ja) 2004-06-29 2005-06-27 インスリン誘発性低血糖の予防および制御のための組成物ならびに方法

Country Status (11)

Country Link
EP (1) EP1778266A4 (enExample)
JP (1) JP2008505087A (enExample)
KR (1) KR20070029276A (enExample)
CN (1) CN101001638A (enExample)
AU (1) AU2005260025A1 (enExample)
CA (1) CA2571030A1 (enExample)
IL (1) IL180361A0 (enExample)
MX (1) MXPA06014970A (enExample)
NO (1) NO20070174L (enExample)
WO (1) WO2006004696A2 (enExample)
ZA (1) ZA200700708B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816114C (en) 2010-11-03 2019-02-12 Jan Jezek Novel composition comprising glucagon
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
CN110446496A (zh) * 2017-02-03 2019-11-12 范德比尔特大学 用于治疗糖尿病的系统、组合物和方法
BR112020000447A2 (pt) * 2017-07-14 2020-07-21 Xeris Pharmaceuticals, Inc. métodos de tratamento de hiperinsulinismo congênito
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
WO2021263197A1 (en) * 2020-06-26 2021-12-30 Xeris Pharmaceuticals, Inc. Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
WO2004046106A1 (en) * 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
Whitehead et al. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery
AU2015204491B2 (en) Rapid action insulin formulations and pharmaceutical delivery systems
JP2020033360A5 (enExample)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2014524480A5 (enExample)
JP2019517542A5 (enExample)
JP2021503468A5 (enExample)
JP2005501110A5 (enExample)
KR102231074B1 (ko) 인슐린 글라진/릭시세나티드 고정비 제형
JP2005520778A5 (enExample)
JP2013522194A5 (enExample)
CN103167878A (zh) 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
ME01546B (me) Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2
CA2971440C (en) Method and compositions for dissolving or solubilizing therapeutic agents
JP2020500864A5 (enExample)
JP2008505087A5 (enExample)
JP2010516671A (ja) 糖尿病の治療のためのエクセナチド及びダラルギンに基づく医薬、その使用及び治療方法
Becker et al. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes
JP2008517991A5 (enExample)
Bush Intensive diabetes therapy and body weight: focus on insulin detemir
WO2019050712A1 (en) SUBLINGUAL EPINEPHRINE TABLETS
US20220265776A1 (en) Combination
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis